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Structure with PTMs
Estrogen receptor b is differentially regulated by alter-
native O-GlcNAcylation/O-phosphorylation at Ser16.
NMR, CD, and molecular dynamics analyses of model
peptides [1] show that these alternative modifications
induce different peptide conformations, providing
a molecular basis for their differential regulation of
protein function.
Protein function is regulated by over two hundred known
posttranslational modifications [2]. In multicellular or-
ganisms, two of the most common and dynamic modifi-
cations of nuclear and cytosolic proteins are Ser(Thr)-
O-phosphorylation and Ser(Thr)-O-b-GlcNAcylation
(attachment of N-acetylglucosamine in a b-glycosidic
linkage to the hydroxyl moiety of serine or threonine).
These two modifications occur on hundreds to thou-
sands of signaling and regulatory proteins. O-GlcNAc
and O-phosphate not only have similar cycling rates,
but also generally occur on the same proteins. Several
site mapping studies have also shown that O-GlcNAc
and O-phosphate can be alternatively attached to the
same serine or threonine residue within a polypeptide
[3]. The reciprocal site occupancy by either O-GlcNAc
or O-phosphate leads to different functional properties
or activities of proteins that have been studied thus
far, including the c-myc oncogene, endothelial nitric ox-
ide synthetase, RNA polymerase II, and estrogen recep-
tor b [3, 4]. The competitive interplay between O-GlcNAc
and O-phosphate cycling is important in nutrient/stress
sensing, transcription, and signaling, and the balance
between O-GlcNAc and O-phosphate on signaling pro-
teins is key to normal cellular metabolism and functions.
For example, tipping the balance of this interplay toward
prolonged increased O-GlcNAcylation underlies glu-
cose toxicity and insulin resistance [5], the hallmark of
type II diabetes.
Estrogen receptors (ER-a and ER-b) are ligand-acti-
vated members of the nuclear receptor family of tran-
scription factors [6]. Upon binding estrogen, the recep-
tors bind to cis-regulatory DNA sequences in the
promoters of target genes and activate specific tran-
scription by physical associations with cofactors and
the transcriptional machinery. Activation of estrogen re-
ceptors also involves phosphorylation at multiple sites
by different kinases, and both types of ER are O-GlcNA-
cylated as well [4, 7]. ER-b shares many structural and
functional features in common with ER-a. However,
ER-b has a different tissue distribution, developmental
profile, and ligand responsiveness. Prior work estab-
lished that ER-b is alternately O-GlcNAcylated or O-
phosphorylated at Ser16 within the N-terminal intrinsi-
cally disordered region of the molecule [4]. Interestingly,
when O-GlcNAcylated at Ser16, ER-b is less active in
stimulating target gene expression, but is more stable
within the cell (Figure 1). In contrast, when ER-b isO-phosphorylated at Ser16, it is more active in stimulat-
ing target gene expression, but paradoxically is rapidly
degraded.
In this issue of Chemistry & Biology, Chen and co-
workers have probed the possible molecular basis for
the reciprocal functions of the O-GlcNAcylation and
O-phosphorylation at Ser16 on ER-b by examining the
solution structures of model ER-b-based peptides [1].
By performing nuclear magnetic resonance (NMR),
circular dichroism (CD), and molecular dynamics simu-
lation experiments on 17-mer unmodified, O-GlcNA-
cylated, or O-phosphorylated peptides, they found that
O-phosphorylation induced a more extended structure,
discouraging the formation of a b-turn in the peptide,
whereas O-GlcNAcylation promoted type II b-turn for-
mation with a tighter turn than found in the unmodified
peptide (Figure 1). In addition, the physical measure-
ments and molecular dynamics analyses revealed sub-
tle differences in the structures of the peptides that
are dependent upon the type of modification at Ser16.
Chen and coworkers’ findings [1] are consistent with
those of Wong et al. [8], who showed that O-GlcNA-
cylation promoted turn-like structures in model peptides
based upon the sequence of the C-terminal domain of
RNA polymerase II, which is also extensively O-GlcNA-
cylated or O-phosphorylated in an alternate fashion [9].
The types of structural comparisons described by
Chen and coworkers [1] are key to elucidating the mo-
lecular bases for the functional significance of the highly
dynamic and regulated interplay between these two
ubiquitous protein modifications. The distinct polypep-
tide conformations induced by each modification not
only could account for different effects on ER-b activity,
but also more broadly could regulate protein:protein in-
teractions, influence subcellular localization and traf-
ficking, and also influence the subsequent decoration
of polypeptides with other types of posttranslational
modifications (PTMs).
While studies with model peptides provide important
insights, we will eventually need to extend both the
structural and functional work to examine posttransla-
tional modification-induced changes in full-length
proteins. When modifications like O-GlcNAc and
O-phosphate alternately occupy the same Ser(Thr) resi-
due, site-directed mutagenesis of the site to a non-
hydroxy amino acid, as is often done in the functional
analysis of phosphorylation, cannot reveal the respec-
tive functions of each modification. Clearly, what is
needed are facile methods to stoichiometrically modify
full-length polypeptides with either O-GlcNAc or
O-phosphate at the specific Ser(Thr) residues that are
alternatively modified in vivo. Availability of these full-
length modified proteins would allow the structure and
the biological functions of each molecular species to
be directly assessed both in vitro and in vivo by protein
transfection into living cells that lack the native protein.
Although Schultz and colleagues [10] have made
advances in the development of these types of site-
specific protein modification methods, the current
approaches have limitations and are not yet readily
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924amenable to widespread use. Despite the considerable
chemical and methodological challenges remaining,
sorting out the distinctive functions of O-GlcNAcylated
or O-phosphorylated forms of regulatory molecules
will be key to understanding the regulation of signaling
Figure 1. Regulation of Estrogen Receptor b by Alternate O-GlcNA-
cylation or O-Phosphorylation at Ser16
O-GlcNAcylation by O-linked N-acetylglucosamine transferase (OGT)
at Ser16 enhances the b-turn conformation at the N terminus, leading
to decreased ER-b activity, but it also results in stabilization of the
protein, increasing its half-life within the cell. In contrast, O-phosphor-
ylation at Ser16 causes the N terminus to adopt a more extended
conformation, leading to increased transcriptional activity, but also
causing the protein to become rapidly degraded within the cell.Chemistry & Biology 13, September 2006 ª2006 Elsevier Ltd All rights reserv
A Noncanonical Path
to Mechanism of Action
Improved methods for discovering small-molecule
mechanisms of action are needed. In this issue of
Chemistry & Biology, Zhang et al. [1] make clever use
of the zebrafish to study the mechanism of the angio-
genesis inhibitor fumagillin and reveal that it targets
the noncanonical Wnt pathway.
Few things are more intriguing in the world of chemical
biology than a small molecule with pronounced biologi-
cal activity and therapeutic importance for which little is
known of its mechanism of action. Deciphering these
molecules’ mechanisms of action can provide surprising
biological insights and avenues for novel therapeutic
approaches. One such small molecule is fumagillin, a
natural product serendipitously discovered to inhibit
endothelial cell proliferation. Fumagillin and its deriva-
tive TNP-470 are potent inhibitors of angiogenesis and
have been the focus of numerous basic and clinical
studies [2]. Although fumagillin has been shown to tar-
get methionine aminopeptidase 2 (MetAP-2) [3], little is
known about how MetAP-2 inhibition exerts its antian-
giogenic influence.and transcription and the assembly of the cytoskeleton,
as well as being important for developing treatments for
diabetes, neurodegenerative disorders, and cancer.
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In this issue of Chemistry & Biology, Zhang et al. [1]
employ a clever combination of in vivo and in vitro ex-
periments to uncover an unexpected connection be-
tween MetAP-2 and noncanonical Wnt signaling. Their
approach takes advantage of the zebrafish, a genetic
model organism for which thousands of mutations and
their phenotypes have been characterized and cata-
loged [4, 5]. Each mutant zebrafish embryo can be
thought of as providing a three-dimensional readout of
a gene’s biological activity. The rich variety of zebrafish
phenotypes makes it possible to characterize in detail
the effects of disrupting a single gene product and to
link a specific embryonic phenotype with the molecular
disruption that causes it. The authors reasoned that
treating zebrafish embryos with TNP-470 might also
produce a distinct phenotype, and that by comparing
the resultant phenotype with those cataloged for zebra-
fish gene mutations, they might be able to learn what
pathway is targeted by TNP-470 (Figure 1).
In many cases, zebrafish embryos can be treated with
small molecules simply by adding the molecules to the
water in which the embryos are developing [6]. When
the authors exposed developing zebrafish embryos to
fumagillin or TNP-470, the embryos developed a defect
in the anterior-posterior axis that resulted in a severely
truncated tail. They also observed the same develop-
mental defect in zebrafish embryos in which MetAP-2
